BeiGene Co.,Ltd Appoints Changzhen Wu As Head Of Manufacturing Operations

BEIJING, Sept. 30, 2015 (GLOBE NEWSWIRE) -- BeiGene, Ltd., a clinical-stage biopharmaceutical company focused on developing molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced the hiring of highly regarded industry veteran Changzhen Wu as Head of Manufacturing Operations. Mr. Wu has a proven track record and the distinctive capabilities in overseeing construction of biopharmaceutical plants and leading manufacturing operations. He will be responsible for all aspects of construction of the Suzhou manufacturing facility. In addition, Mr. Wu will lead manufacturing operations for BeiGene's small-molecules, including production, engineering, quality operations, supply chain, and logistics. He will report to CEO, John V. Oyler and Research Head of Chemistry, Zhiwei Wang.

"Changzhen is an extremely valuable addition to our team," said John V. Oyler, CEO of BeiGene. "He is very well respected and has many established relationships in the industry. His unparalleled knowledge in the production of small-molecule drugs, and overseeing plant construction to managing day to day operations, is a strong complement to our existing team and critical to our future strategies."

Mr. Wu brings over four decades of combined experience in engineering, manufacturing, operations, and process design and development. Prior to joining BeiGene, Mr. Wu was at Pharmacia where he was instrumental in leading the construction of its oncology manufacturing plant in China. Previously, Mr. Wu was the Head Plant Manager at Pfizer Pharmaceutical (WuXi) for over 10 years. Prior to Pfizer, he was the Chief Engineer at Sino-Sweden Pharmaceutical for 15 years. Mr. Wu began his career at China North-West API Pharmaceutical, where he spent over 16 years as a process engineer. He graduated from Shanghai Medical University with a Bachelor's degree in Pharmacology.

"I am thrilled to be joining BeiGene to help scale its operations to address both current needs as well as future opportunities," said Mr. Wu. "We plan to not only grow our manufacturing operations, but also promote and work in conjunction with other divisions of BeiGene to achieve our company goals."

About BeiGene

BeiGene is a global, clinical-stage, research-based company focused on targeted and immuno-oncology therapeutics. With a team of 175+ scientists and staff, BeiGene is advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for cancer. BeiGene is working to create combination solutions that will have both a meaningful and lasting impact on cancer patients. For more information, please visit our website at

CONTACT: Media/Investor Contact: Xin Huang US: +1 917-617-4653 China: +86 185-1406-3050 [email protected]

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

U.K.-based alpha-synuclein biotech Wren will partner with Japanese pharma Eisai to seek out new ways of targeting neuro disorders.

As Moderna continues to drip-feed the latest data from its late-stage COVID-19 vaccine effort, it has updated the shot’s efficacy figure.

Two research teams have discovered drug combinations that may make it possible to translate CAR-T cell therapies to solid tumors.